![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-plan-to-submit-ind-application-for-cid-103-an-anti-cd-38-antibody-in-antibody-mediated-rejection-and-receipt-of-a-non-binding-proposal-to-acquire-entire-china-business-of-the-company-302183227.html
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-15-million-private-placement-financing-by-venrock-healthcare-capital-partners-foresite-capital-panacea-venture-and-dr-wei-wu-he-302183230.html
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-receives-fda-clearance-on-the-investigational-new-drug-ind-application-for-cid-103-in-immune-thrombocytopenia-itp-302145848.html
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-first-quarter-2024-business-and-financial-results-302141100.html
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-reports-development-relating-to-its-disputes-with-juventas-302110387.html
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-fourth-quarter-and-full-year-2023-business-and-financial-results-302101142.html
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-report-positive-interim-phase-1-data-for-bi-1206-in-the-treatment-of-relapsedrefractory-indolent-non-hodgkins-lymphoma-in-china-302079474.html
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-first-dosing-of-folotyn-in-china-302063676.html
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-third-quarter-2023-business-and-financial-updates-301986119.html
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-market-approval-of-cnct19-by-china-nmpa-301981482.html